Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105

Journal of Clinical Oncology

Volumn 33, Issue 17, 2015, Pages 1895-1901

  Telli, Melinda L ^a   Jensen, Kristin C ^a   Vinayak, Shaveta ^a   Kurian, Allison W ^a   Lipson, Jafi A ^a   Flaherty, Patrick J ^a   Timms, Kirsten ^c   Abkevich, Victor ^c   Schackmann, Elizabeth A ^a   Wapnir, Irene L ^a   Carlson, Robert W ^a   Chang, Pei Jen ^a   Sparano, Joseph A ^d   Head, Bobbie ^b   Goldstein, Lori J ^e   Haley, Barbara ^f   Dakhil, Shaker R ^g   Reid, Julia E ^c   Hartman, Anne Renee ^c   Manola, Judith ^h   Ford, James M ^a   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Marin Specialty Care   (United States)

^c Myriad Genetic Laboratories   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g Cancer Center of Kansas   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; INIPARIB; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; DEOXYCYTIDINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLA; BREAST BIOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; GENETIC ASSOCIATION; GENOMIC INSTABILITY; GENOTYPE; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HRD LOH SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; URINARY TRACT INFECTION; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; GENE EXPRESSION PROFILING; GENETICS; MUTATION; PATHOLOGY; PROCEDURES; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84937144479     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.0085     Document Type: Article

References (26)

1. Ford JM, Kastan MB: DNA damage response pathways and cancer, in Niederhuber JE, Armitage JO, Doroshow J, et al (eds): Abeloff's Clinical Oncology (ed 5). Philadelphia, PA, Churchill Livingstone, 2014, pp 142-153
2. Alli E, Sharma VB, Hartman AR, et al: Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 11:7, 2011
3. Bhattacharyya A, Ear US, Koller BH, et al: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899-23903, 2000
4. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
5. Kennedy RD, Quinn JE, Mullan PB, et al: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659-1668, 2004
6. Kriege M, Jager A, Hooning MJ, et al: The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 118:899-907, 2012
7. Telli ML, Ford JM: Novel treatment approaches for triple-negative breast cancer. Clin Breast Cancer 10:E16-E22, 2010 (Suppl 1)
8. Hastak K, Alli E, Ford JM: Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 70:7970-7980, 2010
9. Alli E, Sharma VB, Sunderesakumar P, et al: Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 69:3589-3596, 2009
10. Liu X, Shi Y, Maag DX, et al: Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 18:510-523, 2012
11. Patel AG, De Lorenzo SB, Flatten KS, et al: Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 18:1655-1662, 2012
12. Pierce A, McGowan PM, Cotter M, et al: Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther 14:537-545, 2013
13. Licht S, Cao H, Li Z, et al: Mechanism of action of iniparib: Stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell line. Mol Cancer Ther 10, 2011 (abstr A226)
14. Abkevich V, Timms KM, Hennessy BT, et al: Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107:1776-1782, 2012
15. Birkbak NJ, Wang ZC, Kim JY, et al: Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2:366-375, 2012
16. Popova T, Manié E, Rieunier G, et al: Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72:5454-5462, 2012
17. Vollebergh MA, Lips EH, Nederlof PM, et al: An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 22:1561-1570, 2011
18. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007
19. Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153, 2010
20. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
21. Lehmann BD, Bauer JA, Chen X, et al: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011
22. Masuda H, Baggerly KA, Wang Y, et al: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19:5533-5540, 2013
23. Sikov WM, Berry DA, Perou CM, et al: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2013 (abstr S5-01)
24. Rugo HS, Olopade OI, Demichele A, et al: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 trial. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2013 (abstr S5-02)
25. Alba E, Chacon JI, Lluch A, et al: A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting: Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 136:487-493, 2012
26. von Minckwitz G, Schneeweiss A, Loibl S, et al: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 15:747-756, 2014